A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors.
Loading...
Embargo End Date
ICR Authors
Authors
Gennatas, S
Chamberlain, F
Smrke, A
Stewart, J
Hayes, A
Roden, L
Messiou, C
Kowa, J-Y
Estival, A
Chauhan, D
Thway, K
Fisher, C
van der Graaf, WTA
Jones, RL
Benson, C
Chamberlain, F
Smrke, A
Stewart, J
Hayes, A
Roden, L
Messiou, C
Kowa, J-Y
Estival, A
Chauhan, D
Thway, K
Fisher, C
van der Graaf, WTA
Jones, RL
Benson, C
Document Type
Journal Article
Date
2020-12-01
Date Accepted
2020-08-24
Abstract
INTRODUCTION: Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent oral vinorelbine. MATERIALS AND METHODS: A retrospective review of patients treated with vinorelbine 90 mg orally on days 1, 8, and 15 of a 28-day cycle from January 2004 to July 2019 was performed. Response was assessed using RECIST version 1.1. Descriptive statistics were employed. RESULTS: A total of 29 patients were included. Response rate was 20.7% (6/29), and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%), and diarrhea (4/26, 13.8%). CONCLUSION: Single-agent oral vinorelbine is an effective, safe, and well-tolerated treatment for DT. It represents a new oral alternative for management of DT.
Citation
The Oncologist, 2020, 25 (12), pp. e2013 - e2016
Source Title
The Oncologist
Publisher
OXFORD UNIV PRESS
ISSN
1083-7159
eISSN
1549-490X
1549-490X
1549-490X
Collections
Research Team
Sarcoma&Melanoma Surgery